Two surgeons today reported their experience in performing cell-enhanced
reconstruction on 52 patients from Europe and Israel. The procedures
included breast reconstruction post-partial mastectomy, breast implant
salvage, as well as facial and other cosmetic applications,
demonstrating the increased clinical utility for cell-enhanced
reconstruction.
The results are consistent with previously reported outcomes of
cell-enhanced reconstruction. This is a procedure whereby an autologous
fat graft, enriched with adipose tissue-derived stem and regenerative
cells, is used to correct or fill a soft tissue defect. The stem and
regenerative cells were made available at the time of surgery using
Cytori’s Celution®
800/CRS System. The cases, performed by Claudio Calabrese, M.D.,
Associate Professor of Surgery at The University of Florence Hospital
and Michael Scheflan, M.D., Medical Director of Atidim Medical Center in
Tel Aviv, were reported at the 2008 International Meeting of Oncoplastic
and Reconstructive Breast Surgery.
"We believe enriching autologous fat grafts with adipose tissue-derived
stem and regenerative cells improves volume retention compared to
traditional fat grating,” said Dr. Calabrese. “Evidence
suggests that improved predictability and survivability of a
cell-enhanced fat graft is achieved through improved blood supply and
the reduction of fibrosis within the graft, without the risk of immune
rejection or disease transmission.”
“Both Dr. Calabrese and I independently
observed near-complete volume retention of the fat graft, with some
patients as far out as nine months, and no apparent adverse reactions or
complications,” said Dr. Scheflan. “These
observations are consistent with the growing body of clinical experience
that surgeons from around the world are achieving with cell-enhanced
reconstruction.”
About Cytori
Cytori’s (NASDAQ: CYTX) goal is to be the
global leader in regenerative medicine. The company is dedicated to
providing patients with new options for reconstructive surgery,
developing treatments for cardiovascular disease, and banking patients'
adult stem and regenerative cells. The Celution®
800 System is being introduced in Europe and Asia Pacific into the
reconstructive surgery market while the Celution®
900 System is being commercialized globally for cryopreserving a
patient's own stem and regenerative cells. Clinical trials are ongoing
in cardiovascular disease and planned for spinal disc degeneration,
gastrointestinal disorders, and other unmet medical needs. www.cytoritx.com
Cautionary Statement Regarding Forward-Looking Statements
This press release includes forward-looking statements regarding events,
trends and business prospects, which may affect our future operating
results and financial position. Such statements are subject to risks and
uncertainties that could cause our actual results and financial position
to differ materially. Some of these risks and uncertainties include, but
are not limited to, statements regarding the private placement, the
expected closing of the private placement, the number of additional
shares that could be sold in connection with exercise of warrants issued
in the private placement, a need for further financing, our plans for
expanding commercialization of our Celution®
800/CRS System and for global marketing efforts for our Celution
System-based StemSource®
Cell Bank business, and other risks and uncertainties described under
the heading "Risk Factors" in Cytori’s
Securities and Exchange Commission filings. We assume no responsibility
to update or revise any forward-looking statements to reflect events,
trends or circumstances after the date they are made.
Investor & Media Contact:
Cytori Therapeutics
Tom
Baker, 858-875-5258
tbaker@cytoritx.com
